2Q

RESULTS

Second Quarter 2023

TABLE OF CONTENTS

0 1 E A R N I N G S 2 Q 2 0 2 3

0 2 I N C O M E S T A T E M E N T A N D B A L A N C E

0 3 V A L U A T I O N C L O S E 2 0 2 2

0 4 R J F S H A R E T R E N D S

2Q 2023

R E S U L T S

01

EARNINGS SECOND QUARTER 2023

REIG JOFRE increased 19% in revenue and 25% in EBITDA in the first half of 2023

SALES

+ 19%

€157.2 M

EBITDA

+ 25%

€17.9 M

CONSOLIDATED + 57%

EARNINGS

€5.7 M

  • The sales figure for the first half of 2023 reaches 157 million euros, 19% above the same period of 2022. The medicinal products division, Specialty Pharmacare, leads this growth, followed by the Pharmaceutical Technologies and Consumer Healthcare divisions.
  • Spain represents 46% of revenues, with a sales growth at an exceptional rate of 25%. This is due to the increased manufacturing capacity in injectables, the growth of the Osteoarticular range, and the progression of OTC products in Consumer Healthcare.
  • The Specialty Pharmacare division shows the highest growth, 31%, especially driven by the progression of the Osteoarticular range in Europe. The growth of the other two divisions, Pharmaceutical Technologies and Consumer Healthcare, both with a revenue growth of 14%, is also notable.
  • Reig Jofre achieved an excellent result in the first half of 2023 with a consolidated EBITDA of 17.9 million euros, 25% above the same period of the previous year.
  • Investments in technology have an impact on higher depreciation, mainly due to the new plant in Barcelona.
  • The good financial result, and the contribution of earnings from investee companies allow the Consolidated Earnings to be placed at 5.7 million euros, which represents an increase of 57% compared to 2022.
  • In the first half of 2023, the industrial investments were made for 4 million euros. After capacity expansions in recent years at the Swedish plant, the construction of the new plant in Barcelona and an additional production line in Toledo, the industrial area is now concentrating on technological improvements and the quality and efficiency of processes.

4

INCOME BY BUSINESS UNIT

PHARMACEUTICAL

TECHNOLOGIES

Antibiotics

Injectables / Lyophilised Products

46%

72,1

M i l l i o n s o f

€

+14%

  • The hospital product division grew by 14%, driven both by Spain and by international markets, and especially by Asian countries.
  • Moderate growth of antibiotics, 6%, after a year 2022 in which they grew at double digits.
  • The new injectable plant in Barcelona grew in manufacturing volume, both in its own products and in manufacturing projects for CMO contracts, which allowed it to reach 21% in injectables.
  • International sales

PHARMACEUTICAL 57%

TECHNOLOGIESInternational

SPECIALTY

PHARMACARE

Osteoarticular

Dermatology

31%

48,5

M i l l i o n s o f €

+31%

  • The prescription product division managed to grow 31% in the first half of 2023 (it grew 7% in 2022), standing out as the division with the greatest progression.
  • With a 40% increase in sales, the growth engine is the Osteoarticular range, as well as the CMO activity for the manufacture of enteral gels in the Swedish plant. On its part, Dermatology grew by 7%.
  • On a geographical level, the highest growth continues to occur in Europe and, above all, in Poland, where Reig Jofre created its subsidiary in 2021.

SPECIALTY

PHARMACARE38%

International

CONSUMER

HEALTHCARE

OTC

Energy

Stress and sleep

Weight control

36,6

23%

Beauty

M i l l i o n s o f

€

+14%

  • The Consumer Healthcare division maintained good progress. Spain continued to grow above 20% as in the previous year, and France, its main geographic market, grew by 10%.
  • The Forté Pharma brand of Food Supplements represents more than 80% of revenue. Overall, it grew by 12% in the first semester in its main markets (France, Belgium and Spain), and in online channels.
  • OTC products, in the respiratory and ENT product ranges, grew by 29%, after 2022 in which they grew by 21%.

CONSUMER

HEALTHCARE71%

International 5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Laboratorio Reig Jofre SA published this content on 27 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2023 16:31:20 UTC.